The company manufactures over 185 products spanning the phosphate, sulphate, acetate, chloride, citrate, nitrates, nitrites, carbonate, EDTA derivatives, hydroxide, succinate, and gluconate families.
Its products are supplied to customers in India and more than 20 countries globally, including the US, Argentina, Mexico, Australia, Egypt, Spain, Turkey, UK, Belgium, UAE, and China.
The company’s products are used across a wide spectrum of industries, like pharmaceuticals, scientific and laboratory research, nutraceuticals, biotech, agrochemicals, personal care, metallurgy, and animal health.
Kronox Lab Sciences is a zero debt company with a history of over a decade of operations. The latter makes it easy for potential investors to study its past performance and estimate its future prospects.
For the financial years ended March 31, 2021, 2022, and 2023, the company’s total income increased from Rs 62.46 crore to Rs 82.25 crore to Rs 95.58 crore, while PAT rose from Rs 9.74 crore to Rs 13.54 crore to Rs 16.83 crore, respectively.
The company’s products are supplied in limited quantities for specific use by application industries. Any reduction in the requirement for these products may result in loss of business for the company.
The company’s top 20 products contributed 60.49%, 70.58%, 68.62%, 69.85%, and 70.04% of its revenue for the nine months ended December 31, 2023, and financial years ended December 31, 2022, December 31, 2023, December 31, 2022, and December 31, 2021, respectively.
Most of the sales of the company’s products are to the pharmaceutical industry and for scientific research and laboratory testing. Any change in demand or change in application or processes by the company’s customers in these industries may lead to loss of revenues and profits.
The company’s top 10 customers contributed 45.22%, 53.58%, 50.68%, 56.18%, and 56.32% of its revenue for the nine months ended December 31, 2023, December 31, 2022, FY23, FY22, and FY21, respectively.
This being an offer-for-sale (OFS), the company won’t receive any proceeds from the IPO.